KRW 5130.0
(-1.35%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | 7.13 Billion KRW | -92.97% |
2022 | 101.39 Billion KRW | 31.34% |
2021 | 77.2 Billion KRW | 86.69% |
2020 | 41.35 Billion KRW | 975.45% |
2019 | 3.84 Billion KRW | -29.43% |
2018 | 5.44 Billion KRW | 58.4% |
2017 | 3.43 Billion KRW | 215.52% |
2016 | 1.09 Billion KRW | 81.38% |
2015 | 601.1 Million KRW | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q2 | 1.55 Billion KRW | -20.55% |
2024 Q1 | 1.96 Billion KRW | -5.62% |
2023 Q3 | 1.48 Billion KRW | -27.06% |
2023 Q1 | 1.53 Billion KRW | -19.94% |
2023 FY | 7.13 Billion KRW | -92.97% |
2023 Q4 | 2.07 Billion KRW | 39.95% |
2023 Q2 | 2.03 Billion KRW | 32.33% |
2022 Q1 | 67.93 Billion KRW | 164.79% |
2022 FY | 101.39 Billion KRW | 31.34% |
2022 Q4 | 1.92 Billion KRW | -77.97% |
2022 Q3 | 8.71 Billion KRW | -61.82% |
2022 Q2 | 22.82 Billion KRW | -66.4% |
2021 Q1 | 11.03 Billion KRW | -12.19% |
2021 Q2 | 6.32 Billion KRW | -42.65% |
2021 Q3 | 34.17 Billion KRW | 440.05% |
2021 FY | 77.2 Billion KRW | 86.69% |
2021 Q4 | 25.65 Billion KRW | -24.93% |
2020 Q4 | 12.56 Billion KRW | 209.66% |
2020 Q2 | 24.19 Billion KRW | 4451.43% |
2020 Q1 | 531.57 Million KRW | -48.55% |
2020 FY | 41.35 Billion KRW | 975.45% |
2020 Q3 | 4.05 Billion KRW | -83.23% |
2019 Q3 | 723.1 Million KRW | -36.37% |
2019 FY | 3.84 Billion KRW | -29.43% |
2019 Q4 | 1.03 Billion KRW | 42.88% |
2019 Q2 | 1.13 Billion KRW | 19.31% |
2019 Q1 | 952.42 Million KRW | -47.51% |
2018 Q3 | 1.45 Billion KRW | 0.0% |
2018 Q4 | 1.81 Billion KRW | 24.72% |
2018 FY | 5.44 Billion KRW | 58.4% |
2017 FY | 3.43 Billion KRW | 215.52% |
2016 FY | 1.09 Billion KRW | 81.38% |
2015 FY | 601.1 Million KRW | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
Osang Healthcare Co.,Ltd | 355.84 Billion KRW | 97.996% |
InBody Co.,Ltd | 170.35 Billion KRW | 95.813% |
Curexo Inc. | 72.88 Billion KRW | 90.214% |
Seegene, Inc. | 367.37 Billion KRW | 98.059% |
i-SENS, Inc. | 265.12 Billion KRW | 97.31% |
Ray Co., Ltd. | 145.88 Billion KRW | 95.111% |
Gencurix Inc. | 2.6 Billion KRW | -174.286% |
L&C Bio Co., Ltd | 68.86 Billion KRW | 89.644% |